Jan 12, 2026 11:59AM
Jan 12, 2026 11:58AM
Jul 18, 2025 08:10PM
Jul 18, 2025 07:39PM
Jul 16, 2025 04:01PM
Jul 16, 2025 04:01PM
Jun 16, 2025 07:00AM Sarepta Therapeutics (SRPT) Provides Safety Update for ELEVIDYS
Jun 15, 2025 01:00AM
Jun 4, 2025 09:31AM
Jun 4, 2025 09:30AM
May 16, 2025 09:01AM
May 16, 2025 09:01AM
Jan 13, 2025 12:50PM
Dec 18, 2024 08:30AM Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
May 1, 2024 04:05PM
Feb 28, 2024 04:05PM
Feb 16, 2024 07:00AM
Feb 16, 2024 07:00AM
Jan 16, 2024 09:02AM
Dec 22, 2023 08:01AM
Dec 22, 2023 08:00AM Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Oct 30, 2023 04:20PM
Oct 30, 2023 04:01PM
Aug 2, 2023 04:05PM
Jun 22, 2023 02:02PM
Jun 22, 2023 02:02PM
May 24, 2023 10:52AM
May 24, 2023 09:06AM Citi on Sarepta Therapeutics (SRPT): 'We expect shares to trade towards the $120s today', 'Buy on weakness'
May 24, 2023 08:50AM
May 24, 2023 08:09AM
May 24, 2023 08:00AM
May 23, 2023 04:41AM
May 15, 2023 06:51AM
May 15, 2023 06:40AM
May 15, 2023 06:27AM Inhibrx Inc. (INBX) Mentioned Positive at Evercore, 'Positive Readthrough if SRPT Receives Accelerated Approval'
May 15, 2023 05:37AM
May 12, 2023 07:02PM
May 10, 2023 10:36AM
May 2, 2023 04:05PM
Apr 17, 2023 09:00PM
Apr 14, 2023 05:54AM
Apr 13, 2023 10:39AM Evercore on Sarepta (SRPT) Post Stat News Article: 'probably sets up for the adcomm briefing documents and tone to be somewhat more negative'
Apr 10, 2023 09:37AM
Apr 9, 2023 11:47AM
Apr 4, 2023 08:29AM
Apr 4, 2023 06:21AM
Mar 17, 2023 06:52AM
Mar 17, 2023 03:08AM
Mar 16, 2023 05:44PM Sarepta Therapeutics (SRPT) announced AdCom to be held for SRP-9001
Mar 16, 2023 04:05PM

15,404 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All